Dietary addition of Lactobacillus rhamnosus GG impairs the health of Escherichia coli F4-challenged piglets

1DIPROVAL, University of Bologna, via Rosselli 107, 42100 Reggio Emilia, Italy.
animal (Impact Factor: 1.84). 08/2011; 5(9):1354-60. DOI: 10.1017/S1751731111000462
Source: PubMed


Lactobacillus rhamnosus GG (LGG) is a probiotic for humans and is normally not found in pigs; however, it has been shown to protect the human-derived intestinal Caco-2 cells against the damage induced by an important intestinal pathogen, enterotoxigenic Escherichia coli F4 (ETEC). An experiment was conducted to test whether the dietary addition of LGG improves the growth and health of weaned pigs when orally challenged by E. coli F4. Thirty-six pigs were weaned at 21 days and assigned to a standard weaning diet with or without 1010 CFU LGG (ATCC 53103) per day. The pigs, individually penned, were orally challenged with 1.5 ml of a 1010 CFU E. coli F4 suspension on day 7 and slaughtered on day 12 or 14. With the addition of LGG, the average daily gain and the average daily feed intake were reduced after the challenge with ETEC and for the entire trial (P < 0.05). The average faecal score tended to worsen from day 11 to the end of the trial and the concentration of ETEC in the faeces tended to increase (P = 0.07) with the LGG supplementation. The counts of lactic acid bacteria, enterobacteria and yeasts in the colonic digesta were not affected. The pH values in ileal, colonic and caecal digesta, and the small intestine size were also unchanged. Regardless of the site of measurement (duodenum, jejunum or ileum), a trend of decreased villus height was seen with LGG (P = 0.10). Crypt depth and villus to crypt ratio were unchanged by the diet. A gradual increase of total seric IgA was seen after 1 week and after the challenge, in the control (P < 0.05), but not in the treated group. After the challenge, the LGG reduced the total IgA in the blood serum (P < 0.05), v. the control. The total IgA in the saliva and in the jejunum secretion were not affected by the diet. The F4-specific IgA activity was not affected by the diet at all the samplings. Our result shows that, the administration of LGG do not prevent or reduce the detrimental effect of the E. coli F4 infection on the growth performance and health status of weaned piglet.

Download full-text


Available from: Fabio Coloretti, Mar 18, 2014
  • Source
    • "The aim of many studies is to reduce the burden of this infection through supplementation of various feed additives as spray dried plasma, tryptophan, zinc oxide or probiotics. For controlled infection studies with ETEC that express the F4ab or F4ac fimbriae (Daudelin et al., 2011; Kiarie et al., 2011; Konstantinov et al., 2008; Lessard et al., 2009; Nyachoti et al., 2012; Trevisi et al., 2011) it is essentially necessary to know the susceptibility of the used pigs to ETEC F4ab/ac. The expression and function of the F4ab/ac receptors are genetically determined (Bijlsma and Bouw, 1987). "

    Veterinary Microbiology 08/2012; 162(1). DOI:10.1016/j.vetmic.2012.07.049 · 2.51 Impact Factor
  • Source
    • "Lactobacillus rhamnosus GG (LGG) appears efficacious for preventing acute infectious diarrhoea in children [7], and ETEC-induced diarrhoea in piglets [8]. In contrast, the negative effect on health of F4+ETEC challenged pigs after supplementation with LGG has been reported [9]. Although several possible mechanisms involved in the effects of L. rhamnosus have been investigated, including competitive exclusion or inhibition of pathogens, enhancement of epithelial barrier function, and modulation of both local and systemic host immune responses [10], little is known regarding the action of probiotics on the intestinal mucosa in vivo. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Probiotic could be a promising alternative to antibiotics for the prevention of enteric infections; however, further information on the dose effects is required. In this study, weanling piglets were orally administered low- or high-dose Lactobacillus rhamnosus ACTT 7469 (10(10) CFU/d or 10(12) CFU/d) for 1 week before F4 (K88)-positive Escherichia coli challenge. The compositions of faecal and gastrointestinal microbiota were recorded; gene expression in the intestines was assessed by real-time PCR; serum tumour necrosis factor-α (TNF-α) concentrations and intestinal Toll-like receptor 4 (TLR4) were detected by ELISA and immunohistochemistry, respectively. Unexpectedly, high-dose administration increased the incidence of diarrhoea before F4(+)ETEC challenge, despite the fact that both doses ameliorated F4(+)ETEC-induced diarrhoea with increased Lactobacillus and Bifidobacterium counts accompanied by reduced coliform shedding in faeces. Interestingly, L. rhamnosus administration reduced Lactobacillus and Bifidobacterium counts in the colonic contents, and the high-dose piglets also had lower Lactobacillius and Bacteroides counts in the ileal contents. An increase in the concentration of serum TNF-α induced by F4(+)ETEC was observed, but the increase was delayed by L. rhamnosus. In piglets exposed to F4(+)ETEC, jejunal TLR4 expression increased at the mRNA and protein levels, while jejunal interleukin (IL)-8 and ileal porcine β-defensins 2 (pBD2) mRNA expression increased; however, these increases were attenuated by administration of L. rhamnosus. Notably, expression of jejunal TLR2, ileal TLR9, Nod-like receptor NOD1 and TNF-α mRNA was upregulated in the low-dose piglets after F4(+)ETEC challenge, but not in the high-dose piglets. These findings indicate that pretreatment with a low dose of L. rhamnosus might be more effective than a high dose at ameliorating diarrhoea. There is a risk that high-dose L. rhamnosus pretreatment may negate the preventative effects, thus decreasing the prophylactic benefits against potential enteric pathogens. Our data suggest a safe threshold for preventative use of probiotics in clinical practice.
    PLoS ONE 07/2012; 7(7):e40666. DOI:10.1371/journal.pone.0040666 · 3.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Probiotics are increasingly used in order to help prevent or treat a growing number of conditions, especially gastrointestinal tract disorders. Indeed, a large number of clinical trials, many properly randomized and controlled, have shown significant efficacy in a number of gastrointestinal conditions. However, studies have been very heterogeneous and conclusions are often hard to draw. An issue which has been grossly neglected appears to be that of pharmacokinetics. In fact, studies addressing any type of dose-effect relationship are extremely limited, and drawing conclusions on the relationship between dose and effect for any probiotic species in the context of any specific disorder is close to impossible. This chapter analyzes the available evidence on this aspect, looking at areas such as acute infectious diarrhea, prevention of antibiotic-associated diarrhea, necrotizing enterocolitis, and irritable bowel syndrome. As we acknowledge the paucity of data available on the pharmacokinetics of probiotics and aim to understand more about their mechanisms of action, caution must also be exerted on possible unsafe levels. It is evident that much more solid evidence needs to be provided on the dose-effect relationship of probiotics by analyzing single preparations in rigorously controlled studies that must also aim at establishing possible unsafe or risky levels.
    World review of nutrition and dietetics 04/2013; 107:151-160. DOI:10.1159/000345751
Show more